Oura, the company behind a popular smart ring, has added a tool for people taking Ozempic-style weight-loss drugs, known as GLP-1 medicines. The feature, called GLP-1 Insights, lets users log each dose, note side effects and record their weight, then see all of it next to the sleep, activity and recovery data the ring already collects1. Oura announced it on May 28, 20261.
This is a product launch, not a study. The company describes what the tool records. It has not published data showing that the tool changes anyone’s health or helps them stay on treatment.
What the feature records
Oura says GLP-1 Insights is built around four things: dose tracking, side-effect logging, weight tracking and a layer of personalized insights1. Users can enter their medicine, dose and schedule. They can log common side effects as they happen, including nausea, tiredness, changes in appetite and stomach or gut symptoms, and those entries appear next to the logged doses1.
The app also sends reminders. For a once-a-week shot such as Zepbound, a check-in appears on the day of the dose and first asks whether it was taken. For a daily pill such as Foundayo, it sends daily reminders plus a weekly review of the past week’s doses1. Logging weight is optional. Users can type it in or bring it over from a smart scale through Apple Health or Health Connect1.
Oura’s in-app AI coach, called Oura Advisor, now takes the medicine into account. The company gives an example: if a user’s Readiness Score (Oura’s daily recovery number) drops in the 48 hours after a weekly dose, the coach can point out the pattern and suggest why it might be happening1. Oura describes Advisor as a proprietary AI health coach inside the app2.
The feature works with Oura Ring Gen3 and newer models. It is offered in the United States, the United Kingdom, all European Union countries, Canada, Australia, New Zealand, Mexico, India, the United Arab Emirates, Saudi Arabia, Kuwait and Bahrain1.
Why Oura says it matters
Oura frames the tool around a known problem: many people stop taking these drugs. In a page written for doctors, the company cites an analysis of insurance claims from 4,066 commercially insured adults with obesity who were starting a GLP-1 drug and did not have diabetes. Only 46.3% were still on the drug after 180 days, and 32.3% after one year2.
The same page cites a review that pooled 18 randomized controlled trials (studies where people are assigned by chance to keep or stop a treatment). Oura reports that stopping the drugs reversed much of the benefit, with rises in body weight, waist size, body mass index, blood pressure, fasting blood sugar and HbA1c, a longer-term blood sugar measure2. Oura’s own blog adds a forecast that more than 100 million people worldwide will be using GLP-1 drugs by 20301.
From these numbers, Oura argues that staying on treatment is the central challenge, and says its tool aims to give both patients and doctors a clearer picture of how the body responds over time2. Those figures come from outside studies as summarized by Oura. They are not results from the new feature.
What it does not show yet
None of Oura’s materials report any test of GLP-1 Insights itself. There is no comparison of people who used the tool with people who did not. There are no figures on whether reminders made people more likely to keep taking their medicine, whether side-effect logs led to earlier help from a doctor, or whether ring readings can predict who will do well on these drugs.
The AI coach’s explanations are also untested in the published materials. A dip in a recovery score after a dose is a pattern the app can flag. Whether that dip means anything for a person’s health is a separate question the company has not answered with data.
Oura itself sets limits. It says it does not prescribe medicines, recommend dose changes, or replace the judgment of a clinician1.
Who is behind it
The feature comes from Oura, which sells the ring and a paid membership. It has a commercial tie in this area: Oura names LillyDirect as its preferred partner for access to GLP-1 medicines, in both shot and pill form1. The company also links the feature to its wider metabolic tools, such as a meal log that connects food choices with glucose response, recovery and energy1.
Oura is also pitching the tool to health providers. Its page for clinicians says the feature can give doctors a longer view of how patients respond between visits and help with the months-long period when doses are slowly raised2.
How it fits Oura’s research ties
Oura’s ring has been used in outside research before. In 2021, Oura announced a partnership with researchers at the University of California San Diego to study pregnancy. Ring users with a history of pregnancy were invited to share their past Oura data, including heart rate, heart rate variability, temperature, breathing rate and sleep, along with a short survey3. The lead researcher, assistant professor Benjamin Smarr, aimed to map what normal pregnancy patterns look like and what might change ahead of complications such as preterm birth or miscarriage3. Oura said all findings would be made public3.
In Canada, Sunnybrook Health Sciences Centre registered a study of the Oura ring in adults with myelodysplastic syndromes, a group of blood and bone marrow disorders4. It plans to enroll about 60 people and test whether they can wear the ring 70% of the time for three months, while comparing ring readings with quality-of-life measures4. The registry lists it as an observational study, although its own summary calls it a single-arm phase 2 cohort feasibility study. Its listed main completion date was March 20, 2026, and no results had been posted4.
Other UC San Diego engineers are working on a different kind of ring. In July 2026, a team in Joseph Wang’s lab reported in Nature Communications a prototype ring that reads up to four chemical markers from finger sweat at once, from a list that includes glucose, ketones, vitamin C, uric acid, lactate and alcohol5. In tests with healthy volunteers and people with type 1 diabetes, its glucose readings closely tracked commercial glucose monitors5. That ring is not an Oura product. Its first author noted that commercial rings provide physical readings but lack chemical ones5.
What to watch next
- Whether Oura or outside researchers publish data on people using GLP-1 Insights, especially on how long they stay on their medicine.
- Whether any study tests if ring readings can predict side effects or results on these drugs.
- How doctors and health systems use the clinician version of the tool.
- Results from earlier Oura-based research, such as the Sunnybrook feasibility study, which had not posted results.
